House/Senate 1990 budget compromise
Executive SummaryPassed by full House May 17 and Senate May 18, joint conference report includes $ 100 mil. in "unspecified savings" in the health program, apparently inspired by the Administration's plan to raise $ 100 mil. for FDA through user fees. Endorsement of report clears the way for committee action. FDA budget reconciliation legislation will be marked up by Senate Labor & Human Resources and House Energy & Commerce Committees; Medicare budget is under the jurisdiction of House Ways & Means and Senate Finance Committees. . . .
You may also be interested in...
Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.